EQRx Gets $500M To Hit the Gas on High-Quality, Low-Cost Drug Model

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Is EQRx an Existential Threat to the Biopharma Industry?
EQRx, Exscientia Team Up to Accelerate R&D for Lower-Priced, Better Drugs
EQRx Taps Zeitgeist, Raises $200m For Innovative Drugs at Aggressive Low Prices